Androgens in postmenopausal women: Production, possible role, and replacement options

Obstetrical and Gynecological Survey

Volumn 56, Issue 6, 2001, Pages 361-376

  Lobo, Rogerio A ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; METHYLTESTOSTERONE; NANDROLONE; PRASTERONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE;

ANDROGEN THERAPY; DRUG EFFECT; DRUG EFFICACY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; OVARIECTOMY; OVARY FUNCTION; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY; TREATMENT INDICATION;

ADRENAL GLANDS; AGED; AGING; ANDROGENS; BONE AND BONES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OVARY; POSTMENOPAUSE;

EID: 0034989096     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200106000-00022     Document Type: Review

References (94)

1. Hirsutism, alopecia, and acne
2. Androstenedione is an important precursor of dihydrotestosterone in the genital skin of women and is metabolized via 5α-androstenedione
3. The ratio of androstenedione: 11β-hydroxyandrostenedione is an important marker of adrenal androgen excess in women
4. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle
5. 5α-Reductase activity in the genital skin of hirsute women
6. Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women
7. Measurements of 3α, 17β-androstanediol glucuronide in serum and urine and the correlation with skin 5α-reductase activity
8. Peripheral androgen metabolism (PAM) in postmenopausal (PM) women and the complaint of hirsutism
9. Adrenal and gonadal androgen secretion in normal females
10. Sexual dimorphism in the influence of aging on androgen and estrogen levels: The Rancho Bernardo Study
11. Concordant suppression of serum immunoreactive LH, FSH, alpha subunit, bioactive LH and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix)
12. Endocrine effects and pharmacokinetic characteristics of a potent new GnRH antagonist (Ganirelix) with minimal histamine-releasing properties: Studies in postmenopausal women
13. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin
14. Endocrine function of the postmenopausal ovary: Concentration of androgens and estrogens in ovarian and peripheral vein blood
15. The endocrinology of the menopausal transition: A cross-sectional study of a population-based sample
16. Evolution with ageing of four plasma androgens in postmenopausal women
17. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition
18. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood
19. Twenty-four-hour plasma testosterone concentration declines with age in normal premenopausal women
20. Measurement of androgens-methods and pitfalls
21. Declining adrenal androgens: An association with bone loss in aging women
22. Divergence in adrenal steroid secretory pattern after thermal injury in adult patients
23. Longitudinal evaluation of adrenocortical function in patients infected with the human immunodeficiency virus
24. Aromatase activity in the rat brain: Hormone regulation and sex differences
25. Estradiol and testosterone in specific regions of the human female brain in different endocrine states
26. Hormonal treatments of sexual unresponsiveness in postmenopausal women: A comparative study
27. Sexuality in sexagenarian women
28. A longitudinal study of the effects of menopause on sexuality
29. The female androgen deficiency syndrome
30. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells
31. Androstenedione metabolism in cultured human osteoblast-like cells
32. Identification of androgen receptors in normal human osteoblast-like cells
33. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
34. Aromatase deficiency in a male subject: Characterization of a mutation in the CYP19 gene in an affected family
35. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor
36. 1 (1)-procollagen and transforming growth factor β steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells
37. Androgen and estrogen dynamics in women with vertebral crush fractures
38. The relation between calcium absorption serum DHEA and vertebral mineral density in postmenopausal women
39. Age-related changes in 11β-hydroxyandrostenedione concentration in normal and osteoporotic women
40. Low bioavailable testosterone levels predict future height loss in postmenopausal women
41. Total and free estrogens and androgens in postmenopausal women with hip fractures
42. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
43. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause
44. Skeletal effects of oral estrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women
45. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post menopausal women who have previously received long-term oral oestrogens
46. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women
47. Increased bone mineral density in surgically menopausal women treated with oral estrogen-androgen: A two-year double-blind study comparing two doses each of conjugated estrogens and estrogen-androgen (poster)
48. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women
49. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study
50. Effects of testosterone upon body composition
51. Androgens in rheumatoid arthritis
52. Hormonal and pregnancy relationships to rheumatoid arthritis: Convergent effects with immunological and microvascular systems
53. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis
54. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months
55. Androgen therapy in gynecology
56. Treatment of female menopause with methyltestosterone and stilbestrol
57. Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause
58. Androgen-estrogen treatment in the menopause
59. Low-dosage androgen-estrogen therapy in the older age group
60. Effects on serum lipoprotein cholesterol of estrogen in combination with Δ4-androstenedione, testosterone and methyltestosterone
61. Contemporary therapy of the menopausal syndrome
62. The effects of subcutaneous hormone implants during climacteric
63. The management of persistent menopausal symptoms with oestradiol-testosterone implants: Clinical, lipid and hormonal results
64. Changes in sexual behavior as a function of plasma sex steroid levels in postmenopausal women
65. Androgen enhances sexual motivation in females: A prospective, crossover study of sex steroid administration in the surgical menopause
66. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause
67. The role of androgen in the maintenance of sexual functioning in oophorectomized women
68. A comparison of esterified estrogens with and without methyltestoterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women
69. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy
70. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses
71. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women
72. Conditions modifying the effectiveness of testosterone, testosterone propionate, and methyl testosterone
73. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy
74. Safety surveillance of esterified estrogens-methyl-testosterone (Estratest and Estratest HS) replacement therapy in the United States
75. Interim safety of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women
76. Testosterone relaxes rabbit coronary arteries and aorta
77. Methyltestosterone does not diminish the beneficial effects of estrogen replacement therapy on coronary artery reactivity in cynomolgus monkeys
78. Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys
79. Testosterone, dihydrotestosterone, and oestradiol levels in postmenopausal breast cancer tissues
80. Androgen receptors in breast cancer
81. Endometrial response to estrogen-androgen stimulation
82. Which androgen replacement therapy for women?
83. Subdermal estradiol pellets following hysterectomy and oophorectomy. Effect upon serum estrone, estradiol, luteinizing hormone, follicle-stimulating hormone, corticosteroid binding globulin-binding capacity, testosterone-estradiol binding globulin-binding capacity, lipids, and hot flushes
84. A randomized comparison of nonoral estradiol delivery in postmenopausal women
85. Pharmacokinetics of a novel testosterone matrix transdermal system in health, premenopausal women and women infected with the human immunodeficiency virus
86. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A general clinical research center study
87. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men
88. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age
89. Replacement of dehydroepiandrosterone (DHEA) enhances T-lymphocyte insulin binding in postmenopausal women
90. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life
91. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal man: A clinical research center study
92. Cutaneous application of an androstenedione gel as an in vivo test of 5α-reductase activity in women
93. Metabolism of dihydrotestosterone to 5α-androstane-3α-17β-diol glucuronide is greater in the peripheral compartment that in the splanchnic compartment